Fiscal 2016 was supposed to be the year that Accuray (NASDAQ:ARAY) addressed the doubts that have shadowed the stock for so long - that it was too small and too far behind Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY), that its technology is fundamentally inferior, that radiation oncology centers/administrators don't like/trust it, and that the company is stuck in a perpetual grey zone of inadequate growth and profitability.
Unfortunately, those doubts and concerns are largely still in place, and it is well worth asking whether Accuray can ever generate the growth that med-tech investors want from smaller companies. While there are definite positives in this business (a record backlog, new launches, improving scores in user surveys), there is no such thing as a "must own" stock and investors who think these shares are too much trouble won't get much argument from me at this point.
Read more here:
Accuray Still Not Delivering Acceleration